Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage - PubMed (original) (raw)
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
G M Brodeur et al. Science. 1984.
Abstract
A domain of DNA designated N-myc is amplified 20- to 140-fold in human neuroblastoma cell lines but not in cell lines from other tumor types. N-myc has now been found to be amplified in neuroblastoma tissue from 24 of 63 untreated patients (38 percent). The extent of amplification appears to be bimodal, with amplification of 100- to 300-fold in 12 cases and 3- to 10-fold in 10 others. Amplification was found in 0 of 15 patients with stage 1 or 2 disease, whereas 24 of 48 cases (50 percent) with stage 3 or 4 had evidence of N-myc amplification. These data indicate that N-myc amplification is a common event in untreated human neuroblastomas. Furthermore, N-myc amplification is highly correlated with advanced stages of disease (P less than 0.001) and with the ability to grow in vitro as an established cell line, both of which are associated with a poor prognosis.
Similar articles
- myc gene amplification and expression in primary human neuroblastoma.
Slavc I, Ellenbogen R, Jung WH, Vawter GF, Kretschmar C, Grier H, Korf BR. Slavc I, et al. Cancer Res. 1990 Mar 1;50(5):1459-63. Cancer Res. 1990. PMID: 2302711 - Retrospective study on amplification of N-myc and c-myc genes in pediatric solid tumors and its association with prognosis and tumor differentiation.
Tsuda H, Shimosato Y, Upton MP, Yokota J, Terada M, Ohira M, Sugimura T, Hirohashi S. Tsuda H, et al. Lab Invest. 1988 Sep;59(3):321-7. Lab Invest. 1988. PMID: 3411933 - Gene amplification in human neuroblastomas: basic mechanisms and clinical implications.
Brodeur GM, Seeger RC. Brodeur GM, et al. Cancer Genet Cytogenet. 1986 Jan 1;19(1-2):101-11. doi: 10.1016/0165-4608(86)90377-8. Cancer Genet Cytogenet. 1986. PMID: 3940169 - N-myc oncogene and stage IV-S neuroblastoma. Preliminary observations on ten cases.
Nakagawara A, Sasazuki T, Akiyama H, Kawakami K, Kuwano A, Yokoyama T, Kume K. Nakagawara A, et al. Cancer. 1990 May 1;65(9):1960-7. doi: 10.1002/1097-0142(19900501)65:9<1960::aid-cncr2820650914>3.0.co;2-4. Cancer. 1990. PMID: 2196987 Review. - Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?--An overview.
Tsuchida Y, Hemmi H, Inoue A, Obana K, Yang HW, Hayashi Y, Kanda N, Shimatake H. Tsuchida Y, et al. Tumour Biol. 1996;17(2):65-74. doi: 10.1159/000217968. Tumour Biol. 1996. PMID: 8658015 Review.
Cited by
- Early evolutionary branching across spatial domains predisposes to clonal replacement under chemotherapy in neuroblastoma.
Karlsson J, Yasui H, Mañas A, Andersson N, Hansson K, Aaltonen K, Jansson C, Durand G, Ravi N, Ferro M, Yang M, Chattopadhyay S, Paulsson K, Spierings D, Foijer F, Valind A, Bexell D, Gisselsson D. Karlsson J, et al. Nat Commun. 2024 Oct 18;15(1):8992. doi: 10.1038/s41467-024-53334-x. Nat Commun. 2024. PMID: 39419962 Free PMC article. - Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status.
Wei Z, Gong B, Li X, Chen C, Zhao Q. Wei Z, et al. BMC Cancer. 2024 Oct 15;24(1):1279. doi: 10.1186/s12885-024-13044-5. BMC Cancer. 2024. PMID: 39407175 Free PMC article. - A temporal (phospho-)proteomic dataset of neurotrophic receptor tyrosine kinase signalling in neuroblastoma.
Maher S, Wynne K, Zhernovkov V, Halasz M. Maher S, et al. Sci Data. 2024 Oct 10;11(1):1111. doi: 10.1038/s41597-024-03965-y. Sci Data. 2024. PMID: 39389992 Free PMC article. - Exploring the dynamics and interactions of the N-myc transactivation domain through solution nuclear magnetic resonance spectroscopy.
Rejnowicz E, Batchelor M, Leen E, Ahangar MS, Burgess SG, Richards MW, Kalverda AP, Bayliss R. Rejnowicz E, et al. Biochem J. 2024 Nov 6;481(21):1535-1556. doi: 10.1042/BCJ20240248. Biochem J. 2024. PMID: 39370942 Free PMC article. - Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma.
Nagarajan D, Parracho RT, Corujo D, Xie M, Kutkaite G, Olsen TK, Rubies Bedos M, Salehi M, Baryawno N, Menden MP, Chen X, Buschbeck M, Mao Y. Nagarajan D, et al. J Clin Invest. 2024 Sep 10;134(21):e175310. doi: 10.1172/JCI175310. J Clin Invest. 2024. PMID: 39255035 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical